These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 8541551

  • 1. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
    Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N.
    Blood; 1995 Dec 15; 86(12):4603-11. PubMed ID: 8541551
    [Abstract] [Full Text] [Related]

  • 2. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
    van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC.
    Blood; 1996 Jun 15; 87(12):5213-7. PubMed ID: 8652835
    [Abstract] [Full Text] [Related]

  • 3. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
    Honda H, Oda H, Suzuki T, Takahashi T, Witte ON, Ozawa K, Ishikawa T, Yazaki Y, Hirai H.
    Blood; 1998 Mar 15; 91(6):2067-75. PubMed ID: 9490692
    [Abstract] [Full Text] [Related]

  • 4. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
    Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa Si, Ishikawa T, Yazaki Y, Hirai H.
    Blood; 2000 Feb 15; 95(4):1144-50. PubMed ID: 10666183
    [Abstract] [Full Text] [Related]

  • 5. Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
    Winter SS, Greene JM, McConnell TS, Willman CL.
    Leukemia; 1999 Dec 15; 13(12):2007-11. PubMed ID: 10602422
    [Abstract] [Full Text] [Related]

  • 6. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis.
    Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, de Micheli D, Parziale A, Fornaci MN, Martinelli G, Salvatore F.
    Blood; 1996 Feb 01; 87(3):1075-80. PubMed ID: 8562932
    [Abstract] [Full Text] [Related]

  • 7. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA.
    J Exp Med; 1999 May 03; 189(9):1399-412. PubMed ID: 10224280
    [Abstract] [Full Text] [Related]

  • 8. The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives.
    Klco JM, Kreisel FH, Zehnbauer BA, Kulkarni S, Hassan A, Frater JL.
    Am J Hematol; 2008 Dec 03; 83(12):901-7. PubMed ID: 18932238
    [Abstract] [Full Text] [Related]

  • 9. Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
    Suh SP, Kee SJ, Lim WH, Song JW, Lee SK, Kim JP, Shin JH, Ryang DW.
    Clin Chem Lab Med; 2000 Sep 03; 38(9):939-44. PubMed ID: 11097354
    [Abstract] [Full Text] [Related]

  • 10. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D, Hanenberg H, Lion T, Burdach S.
    Leukemia; 1995 Mar 03; 9(3):419-24. PubMed ID: 7885040
    [Abstract] [Full Text] [Related]

  • 11. T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).
    Xia T, Yang Y, Li G, Chang J, Li J, Ren F, Ren W, Wang H, Xu Z.
    J Clin Lab Anal; 2020 Jun 03; 34(6):e23241. PubMed ID: 32052899
    [Abstract] [Full Text] [Related]

  • 12. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
    Serrano J, Roman J, Sanchez J, Jimenez A, Castillejo JA, Herrera C, Gonzalez MG, Reina L, Rodriguez MC, Alvarez MA, Maldonado J, Torres A.
    Blood; 2000 Apr 15; 95(8):2659-65. PubMed ID: 10753848
    [Abstract] [Full Text] [Related]

  • 13. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation.
    Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Simões MA, Kreil S, Ward D, Hidalgo-Curtis C, Melo JV, Wiemels J, Nadel B, Cross NC, Grand FH.
    Leukemia; 2010 Oct 15; 24(10):1742-50. PubMed ID: 20703256
    [Abstract] [Full Text] [Related]

  • 14. [Sequential analysis of p210- and p190-bcr-abl by RT-PCR after allogeneic bone marrow transplantation for p210/p190-bcr-abl double positive acute lymphoblastic leukemia].
    Fujimaki K, Maruta A, Yoshida M, Yamazaki E, Motomura S, Kodama F, Matsuzaki M, Fujisawa S, Kanamori H, Ishigatsubo Y.
    Rinsho Ketsueki; 2001 Feb 15; 42(2):89-93. PubMed ID: 11280922
    [Abstract] [Full Text] [Related]

  • 15. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
    Heisterkamp N, Voncken JW, Senadheera D, Gonzalez-Gomez I, Reichert A, Haataja L, Reinikainen A, Pattengale PK, Groffen J.
    Blood; 2000 Sep 15; 96(6):2226-32. PubMed ID: 10979970
    [Abstract] [Full Text] [Related]

  • 16. Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
    Scrideli CA, de Oliveira FM, Brassesco MS, de Paula Queiroz R, Bernardes JE, Valera ET, Tone LG.
    Leuk Res; 2009 Mar 15; 33(3):495-9. PubMed ID: 18495245
    [Abstract] [Full Text] [Related]

  • 17. Restricted oncogenicity of BCR/ABL p190 in transgenic mice.
    Voncken JW, Griffiths S, Greaves MF, Pattengale PK, Heisterkamp N, Groffen J.
    Cancer Res; 1992 Aug 15; 52(16):4534-9. PubMed ID: 1643646
    [Abstract] [Full Text] [Related]

  • 18. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.
    Adnan-Awad S, Kim D, Hohtari H, Javarappa KK, Brandstoetter T, Mayer I, Potdar S, Heckman CA, Kytölä S, Porkka K, Doma E, Sexl V, Kankainen M, Mustjoki S.
    Leukemia; 2021 Jul 15; 35(7):1964-1975. PubMed ID: 33168949
    [Abstract] [Full Text] [Related]

  • 19. Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
    Yuanxin Y, Yanhong Z, Qin Z, Sishi T, Yang D, Yi Z, Minjin W, Juan Z, Xiaojun L, Lanlan W, Binwu Y.
    Leuk Res; 2019 Apr 15; 79():6-16. PubMed ID: 30784762
    [Abstract] [Full Text] [Related]

  • 20. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.
    Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G, Nwachukwu B, Kim P, Guo J, Kamel-Reid S.
    Br J Haematol; 1998 Dec 15; 103(3):711-5. PubMed ID: 9858221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.